Logo

Regeneron Reports IDMC Clearance of Efficacy for REGEN-COV (Casirivimab + Imdevimab) in P-III COVID-19 Outpatient Outcomes Trial

Share this

Regeneron Reports IDMC Clearance of Efficacy for REGEN-COV (Casirivimab + Imdevimab) in P-III COVID-19 Outpatient Outcomes Trial

Shots:

  • Regeneron reported changes to the P-III study assessing REGEN-COV in non-hospitalized patients with COVID-19- following recommendations from the IDMC
  • The IDMC found clear clinical efficacy in reducing the rate of hospitalization and death with both doses (1-200 & 2-400 mg) of REGEN-COV vs PBO. The company will immediately stop enrolling patients in the PBO group- following the IDMC’s recommendation
  • The trial will continue to enroll patients in both treatment arms. IDMC has also reassured that REGEN-COV effectively neutralizes emerging strains of the virus in its preclinical data

 ­ Ref: Regeneron | Image: The Print

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions